Core Insights - Septerna, Inc. has appointed Dr. Keith Gottesdiener to its board of directors, who will chair a newly formed R&D Committee, bringing over 30 years of biotechnology experience [1][2] - Dr. Gottesdiener's expertise in advancing therapeutics and regulatory strategy is expected to support Septerna's lead programs and pipeline development [2] - The company is focused on GPCR drug discovery through its proprietary Native Complex Platform™, aiming to address unmet medical needs across various therapeutic areas [3] Company Overview - Septerna, Inc. is a clinical-stage biotechnology company specializing in GPCR therapies, with a strong team of experts and a diverse pipeline of oral small molecule drug candidates [3] - The company is advancing programs in endocrinology, immunology, inflammation, and metabolic diseases, both independently and in collaboration with partners [3] Leadership Background - Dr. Gottesdiener has held significant leadership roles, including President and CEO of Prime Medicine, Inc., and CEO of Rhythm Pharmaceuticals, Inc., where he oversaw the approval of setmelanotide for three obesity indications [2] - His previous experience includes 16 years at Merck Research Laboratories, where he was responsible for the approval of over 20 novel therapeutics and more than 200 IND submissions [2]
Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors